Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Manns MP, et al. Among authors: sulkowski ms. Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9. Liver Int. 2014. PMID: 24118703 Clinical Trial.
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
Sulkowski MS, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, Ball L, Khalili M, Dieterich DT; Hepatitis Resource Network Clinical Trials Group. Sulkowski MS, et al. J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):464-72. doi: 10.1097/00126334-200404150-00004. J Acquir Immune Defic Syndr. 2004. PMID: 15021311 Clinical Trial.
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE; AIDS Clinical Trials Group A5088 Protocol Team. Glesby MJ, et al. J Infect Dis. 2005 Mar 1;191(5):686-93. doi: 10.1086/427812. Epub 2005 Jan 26. J Infect Dis. 2005. PMID: 15688281 Clinical Trial.
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group. Poynard T, et al. Gastroenterology. 2009 May;136(5):1618-28.e2. doi: 10.1053/j.gastro.2009.01.039. Epub 2009 Jan 22. Gastroenterology. 2009. PMID: 19208349 Clinical Trial.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. McHutchison JG, et al. Among authors: sulkowski ms. N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. N Engl J Med. 2009. PMID: 19625712 Free article. Clinical Trial.
Telaprevir for previously treated chronic HCV infection.
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. McHutchison JG, et al. N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014. N Engl J Med. 2010. PMID: 20375406 Free article. Clinical Trial.
355 results